The prospect of obtaining meaningful biochemical data from post-mortem human brain may be questioned for a variety of reasons. However, such studies have indicated neurotransmitter abnormalities in the neurodegenerative diseases of Parkinson, Huntington and Alzheimer (Ehringer & Hornykiewicz, 1960; Bird & Iversen, 1974; Bowen et a[., 1976) . Neurochemical measures may be influenced by many factors, such as patient age, sex and drug history, immediate pre-mortem status (sudden death or prolonged coma) and post-mortem delay (the delay between death and freezing of the brain). lnterpretation of the results of post-mortem studies therefore requires fastidious consideration of these factors in order to separate changes that are due to disease from those that occur as a result of epiphenomena. The present report will consider the validity of a number of neurochemical measures by reviewing recent studies of Alzheimer's disease from this laboratory.
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The concentrations of serotonin (5-HT), 5-hydroxyindoleacetic acid (SHIAA), noradrenaline (NA), 3-methoxy-4-hydroxyphenylglycol (MHPG) , dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), aspartic acid (Asp), glutamic acid (Glu), yaminobutyric acid (GABA) and somatostatin-like immunoreactivity (SLIR), together with the activities of phosphate-activated glutaminase (PAG) and choline acetyltransferase (ChAT ), were determined as described elsewhere Palmer et al., 1987u,b,c; Procter et al., 1988a) . Table 1 shows that in the temporal cortex, concentrations of 5-HT, NA, DA, DOPAC and SLIR, together with PAG activity, were all lower in post-mortem tissue than in tissue Abbreviations used: 5-HT, serotonin; 5-HIAA, S-hydroxyindoleacetic acid; NA, noradrenaline; MHPG, 3-methoxy-4-hydroxyphenylglycol; DA, dopamine; DOPAC, dihydroxyphenylacetic acid; HVA, homovanillic acid; GABA, y-aminobutyric acid; SLIR, somatostatin-like immunoreactivity; PAC, phosphate-activated glutaminase; ChAT, choline acetyltransferase; GAD, glutamic acid decarboxylase. removed unte mortem. By contrast, the concentrations of MHPG, HVA, Asp, Glu and GABA were all higher in postmortem tissue. Despite these differences, only 5-HT and MHPG concentrations (in both frontal and temporal cortex) and ChAT activity (in the lateral occipital gyrus only) were found to correlate significantly with post-mortem delay ( Table 2) . Thus, the lack of a significant correlation with post-mortem delay does not seem to be a good indicator of post-mortem stability. Allowance for the influence of postmortem delay and age ( Table 2) is normally made by matching control and disease tissue with respect to these variables. It is also preferable to have a similar proportion of male and females in each group although none of the neurochemical measures was different in male and female brains, except for the concentration of 5-HIAA in the orbital frontal cortex, which was higher in females than in males ( Table 2) .
A factor that influences neurochemical measures in postmortem tissue is the clinical state of the patient in the period immediately before death. This is particularly relevant to the study of neurodegenerative disease as such patients often have a protracted death, usually as a result of bronchopneumonia. McGeer et al. ( 1971) and Bowen et ul. ( 1976) were among the first to report that prolonged terminal illness, in which death is often associated with coma, can adversely affect subsequent post-mortem neurochemical measures. In particular, reduced activities of the enzymes tyrosine hydroxylase, aromatic amino acid decarboxylase and glutamic acid decarboxylase (GAD) were reported in all brain regions of patients dying after prolonged terminal illness. The importance of the agonal state, particularly in determining post-mortem G A D activity, has since been confirmed Perry et al., 1977; Spillane ef al., 1977; Spokes, 1979; Spokes et ul., 1979; Perry et ul., 1982) . Surprisingly, concentrations of GABA have not been shown to be similarly affected in subcortical structures (Spokes et a[., 1979) , although GABA concentrations have recently been shown to be affected by agonal state in the parietal cortex (Table 2 ). PAG activity, previously shown to be influenced by this factor (Butterworth et ul., 1983) , was subject to wide variability that was unexplained.
Many patients with Alzheimer's disease and other neurodegenerative disorders will have been receiving medication. The effect of this on neurochemical measures is particularly difficult to investigate since multiple drug regimens are common in elderly or hospitalized patients. It is not usually possible to match control and pathological groups with regard to drug treatment, so it is important to (14) 1.3f0.1 (14) 1.8 k0.5 (13)
17.1 k 0.7 ( 10) 1 18.4 f 5.3 (14) 19.3 f 1.0 (10) 1.4 k 0.3 (8) 11.2+0.6(6) 9 1 f 8 ( 1 2 ) O.Sk0.l (8) Table 2 shows that only SLlR concentration (in the inferior temporal gyrus) and ChAT activity (in the inferior parietal lobule and posterior cingulate gyrus) were affected by drug treatment. Assessment of the influence of factors (such as agonal state and drug treatment) in Alzheimer subjects will be complicated by the severity of the disease. Post-mortem tissue may generally be expected to reflect the end-stages of disease processes. However, it is possible that younger patients die following a more severe form of the disease or that older, more frail, patients die at an earlier stage of the disease. This appears to be the case in Alzheimer's disease as the concentrations of 5-HT, NA and SLlR and ChAT activity have been found to be more severely affected in subjects less than 80 years of age than in older subjects (Bowen et al., 1979;  Rossor el al., 1984; Francis et al., 1985) .
It can be difficult to interpret neurochemical data from diseased post-mortem brain because reductions in the volume of some brain regions may occur, together with alterations in the relative proportion of neurons and glial cells. The widespread practice of expressing neurochemical data per unit of tissue protein or per unit wet weight of tissue, clearly does not make allowance for any atrophy. If this occurs equally in all cellular components, there may be no change in neurochemical measures, even in severely atrophied tissue. Conversely, shrinkage of some, but not other, components could lead to an apparent increase in unaffected components. Tissue atrophy, particularly in the cerebral cortex, is a feature of Alzheimer's disease (Najlerahim & Bowen, 19881 , but only a few studies attempt to make allowance for this (Bowen et al., 1979; Palmer et al., 1988; Procter et al., 1 9 8 8~) .
Neurochemical measures in Alzheimer's disease
Data for a number of neurochemical measures in the temporal cortex of subjects with Alzheimer's disease are summarized in Table 3 . The concentrations of 5-HT and NA and ChAT activity were reduced in tissue obtained ante mortem as well as in all post-mortem studies. These changes, BIOCHEMICAL SOCIETY TRANSACTIONS The interval between the emergence of symptoms of Alzheimer's disease and neurosurgery was 3-4 years, whereas death typically occurs much later (e.g. some 8 years after onset, as in the series with a 2 h delay). Percentages are given only for values that were significantly different from control. NS, not significant; -, not determined. Superscript numbers indicate reference: ; *Lowe et al. ( 1988); 3Palmer el al. (1987a) ; 'Palmer ef al. (19876) ; 'Palmer et ul. ( 1 9 8 7~) ; hPalmer et al. (1988); 7Procter et al. (1988a) ; XProcter et al. ( 1 988 b) ; 
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together with loss of related markers (uptake of ['HIS-HT and ("HJNA and synthesis of radiolabelled acetylcholine), probably index loss of serotonergic, noradrenergic and cholinergic neurons, as suggested by morphometric studies (Palmer et al., 1987a,b) . By contrast, dopaminergic markers (concentrations of DA, DOPAC and HVA) were consistently unaltered, as was the concentration of the major metabolite of NA, MHPG. 5-HIAA concentration was reduced in all studies except the one with the longest post-mortem delay, so this discrepant result may be related to post-mortem changes in 5-HT concentration. Concentrations of Asp and Glu and PAG activity are putative markers of neurons that release excitatory dicarboxylic amino acids (see Schousboe, 1987) . However, concentration determinations do not separate neurotransmitter from metabolic pools of Asp and Glu and PAG activity is both unstable post mortem and subject to unexplained variability ( Table 1 ; Svenneby et al., 1986; Procter et af., 1988a) . Thus, ante-mortem changes in Asp and Glu concentrations may reflect altered metabolism and changes in PAG activity post mortem are probably not related to the Alzheimer's disease process. SLIR and GABA concentrations and G A D activity were also reduced post mortem, but not ante mortem, suggesting that either the changes seen post mortem are artefactual, or the measures are affected only at a relatively late stage of the disease.
Are post-mortem biochemical studies worthwhile?
Once it has been satisfactorily established that a change in a particular neurochemical measure is real and not an artefact, it is important to attempt to determine whether the observed change is relevant to both the clinical and pathological course of the disease. Relating neurochemical values to behavioural measures is difficult with post-mortem tissue because of the preponderance of severely affected subjects and the variable and often prolonged duration between clinical assessment and death. Similarly, relating neurochemical values to pathology is complicated by the common practice of using one brain hemisphere for biochemical analysis and the other for pathological examination. Tissue removed ante mortem from Alzheimer patients has overcome both of these shortcomings and has confirmed postmortem correlations between (i) a serotonergic marker and the number of neurofibrillary tangles and (ii) cholinergic markers and both senile plaque formation and mental state (Perry et a[., 1981; Mountjoy et al., 1984; Francis et al., 1985; Neary et al., 1986; Palmer et a[., 1 9 8 7~~) .
Thus, correction of the cholinergic deficit is probably essential for significant clinical improvement and a recent therapeutic trial (Summers et al., 1986 ) of a centrally acting actylcholinesterase inhibitor (tetrahydroaminoacridine) supports this approach. Post-mortem studies have also led to rational therapy for another common neurodegenerative disorder, Parkinson's disease, but not the rarer condition of Huntington's disease. Thus, post-mortem studies seem to have successfully addressed disorders with widespread social and economic importance (see Sims et al., 198 1,1983 ).
In conclusion, biochemical studies of post-mortem brain have made important contributions to understanding the pathophysiology of Alzheimer's disease. However, without data from tissue obtained ante mortem, it would have been difficult to separate disease-related changes occurring quite soon after the emergence of symptoms from later changes and artefacts. Post-mortem measurements therefore need to be complemented by ante-mortem data. Neuroimaging techniques in vivo may eventually provide non-invasive approaches (McGeer, 1986) , but complex volumetric analyses will probably be required to make allowance for tissue atrophy in studies using positron emission tomography (see Chawluk et al., 1987) and the application of localized nuclear magnetic resonance spectroscopy to human brain is still in its infancy. Until such techniques are improved, biochemical post-mortem studies will remain an important means for investigating diseases of the brain.
